Important regulatory notice. No peptide is currently licensed by the MHRA as a treatment for Alzheimer’s disease. This page is a literature-context overview of compound families discussed in the published Alzheimer’s research record. It is not personal-use guidance and Peptides Lab UK does not endorse or recommend any human or veterinary use of any unlicensed peptide for Alzheimer’s or any other clinical indication.
Quick research summary. The published Alzheimer’s research literature has explored several peptide and peptide-related compound families in cell-culture and animal-model contexts relevant to the disease biology. The compounds discussed below appear in that research record. None is a licensed UK treatment for Alzheimer’s disease. Anyone affected by Alzheimer’s should be referred through standard NHS dementia care pathways.
Disease biology context
Alzheimer’s disease is characterised in the published literature by extracellular amyloid-beta plaque deposition, intracellular tau hyperphosphorylation and neurofibrillary tangle formation, microglial neuroinflammatory activity, cholinergic neuronal loss in defined brain regions, and synaptic-density reduction. Each pathology axis has generated its own research literature on candidate intervention pathways.
Compound families that appear in the published Alzheimer’s research record
Cell-culture and animal-model studies relevant to Alzheimer’s biology have discussed several peptide and peptide-related families. Examples include amyloid-targeting peptide candidates (mostly in preclinical stages), tau-targeting peptide candidates, neurotrophic peptide candidates relevant to BDNF and NGF biology, neuroinflammation-modulating peptides, and metal-chelating peptide candidates relevant to iron and copper biology in Alzheimer’s. These are research-context compound categories. None is a licensed treatment for Alzheimer’s disease in the United Kingdom.
Where licensed Alzheimer’s treatments fit
The current MHRA-licensed pharmacological treatments for Alzheimer’s in the UK are the cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, used within NHS dementia care pathways. The disease-modifying anti-amyloid antibody therapies (lecanemab, donanemab) have been the subject of ongoing UK regulatory consideration. None of these are peptides supplied as research-use-only reference compounds.
UK regulatory position
No peptide sold as a research-use-only reference compound is licensed for Alzheimer’s disease in the UK. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. Marketing peptides as Alzheimer’s interventions in the UK is inside the medicines framework.
For laboratory researchers
Researchers working in Alzheimer’s biology may use peptide reference compounds for in-vitro and animal-model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling. Peptides Lab UK supplies on that basis.
For families of people with Alzheimer’s
Standard care pathways are through the NHS, your GP and specialist dementia services. The Alzheimer’s Society (alzheimers.org.uk) and Dementia UK (dementiauk.org) are useful UK resources.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. No peptide on this site is a licensed treatment for Alzheimer’s disease in the United Kingdom.
